We are live on
!
Find out more
GGI
GordonMD Global Investments Portfolio holdings
AUM
$207M
This Fund
S&P 500
This Quarter
Est. Return
+1.79%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$144M
AUM Growth
+$4.1M
(+2.9%)
Cap. Flow
+$20.6M
Cap. Flow
% of AUM
14.35%
Top 10 Holdings %
Top 10 Hldgs %
82.42%
Holding
16
New
3
Increased
2
Reduced
8
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$15.7M |
| 2 |
Scholar Rock
SRRK
|
+$5.94M |
| 3 |
SION
Sionna Therapeutics
SION
|
+$5.19M |
| 4 |
Vir Biotechnology
VIR
|
+$4.69M |
| 5 |
Allogene Therapeutics
ALLO
|
+$2.87M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crinetics Pharmaceuticals
CRNX
|
+$4.34M |
| 2 |
Taysha Gene Therapies
TSHA
|
+$2.76M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$1.68M |
| 4 |
Kyverna Therapeutics
KYTX
|
+$1.22M |
| 5 |
Incyte
INCY
|
+$1.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kyverna Therapeutics
KYTX
$547M
| $36.6M | 25.51% |
4,244,818
-147,000
| -3% | -$1.22M |
|
|
2
Taysha Gene Therapies
TSHA
$2.02B
| $22.2M | 15.47% |
737,550
-593,351
| -45% | -$2.76M |
|
|
3
Vir Biotechnology
VIR
$1.81B
| $13.6M | 9.48% |
1,518,552
+588,235
| +63% | +$4.69M |
|
4
Bausch + Lomb
BLCO
$6.16B
| $9.12M | 6.35% |
573,472
-40,000
| -7% | -$680K |
|
5
Amgen
AMGN
$239B
| $7.11M | 4.95% |
20,212
-3,000
| -13% | -$1.07M |
|
|
6
Scholar Rock
SRRK
$7.09B
| $6.51M | 4.54% |
+132,500
| New | +$5.94M |
|
7
Ultragenyx Pharmaceutical
RARE
$2.61B
| $6.06M | 4.22% |
289,101
-40,000
| -12% | -$901K |
|
8
Pyxis Oncology
PYXS
$255M
| $6.02M | 4.19% |
4,121,870
| – | – |
|
|
9
Teva Pharmaceuticals
TEVA
$44.4B
| $5.62M | 3.91% |
1,257,495
+487,945
| +63% | +$15.7M |
|
|
SION
10
Sionna Therapeutics
SION
$283M
| $5.45M | 3.8% |
+136,000
| New | +$5.19M |
|
11
Celldex Therapeutics
CLDX
$3.24B
| $5.4M | 3.76% |
170,307
| – | – |
|
12
Insmed
INSM
$27.1B
| $4.67M | 3.26% |
28,587
| – | – |
|
|
13
Crinetics Pharmaceuticals
CRNX
$9B
| $4.61M | 3.21% |
126,985
-97,150
| -43% | -$4.34M |
|
|
14
Incyte
INCY
$26.3B
| $4.08M | 2.84% |
43,300
-11,200
| -21% | -$1.12M |
|
|
15
Allogene Therapeutics
ALLO
$750M
| $3.49M | 2.43% |
+1,430,000
| New | +$2.87M |
|
|
16
Tarsus Pharmaceuticals
TARS
$3.14B
| $2.99M | 2.09% |
42,680
-24,000
| -36% | -$1.68M |
|
Similar funds
AWS
OPF
AWP
MKW
SPI
AP
HI
HA
GordonMD Global Investments's Q1 2026 Portfolio in Review
As of Q1 2026, GordonMD Global Investments held 16 positions worth $144M, up 2.9% from $139M the previous quarter. Its ten largest holdings account for 82% of the portfolio.
GordonMD Global Investments deployed $20.6M of net new capital in Q1 2026, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Scholar Rock: 132,500 shares worth $6.51M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $4.34M trimmed.
- GordonMD Global Investments's largest Q1 2026 buy was Scholar Rock: 132,500 shares worth $6.51M.
- GordonMD Global Investments added most to Teva Pharmaceuticals in Q1 2026, an estimated $15.7M increase.
- GordonMD Global Investments's biggest Q1 2026 reduction was Crinetics Pharmaceuticals, cutting an estimated $4.34M.
- GordonMD Global Investments's ten largest holdings make up 82% of its $144M portfolio in Q1 2026.
- GordonMD Global Investments opened 3 new positions and closed 0 in Q1 2026.
- GordonMD Global Investments's portfolio value rose 2.9% quarter-over-quarter to $144M.
Based on GordonMD Global Investments's 13F filing for Q1 2026, filed 15 May 2026.